Most cited papers from Celltrion (South Korea)

Celltrion (South Korea)

What are the most cited papers from Celltrion (South Korea)?

The most cited paper from Celltrion (South Korea) is "A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study" (Dae‐Hyun Yoo, Paweł Hrycaj, Pedro Cavaleiro Miranda et al., 2013), with 655 citations. Next come "A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study" (607) and "Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study" (343).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 32 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Dae‐Hyun Yoo, Paweł Hrycaj, Pedro Cavaleiro Miranda et al. · Annals of the Rheumatic Diseases Open access	18 May 2013	655
2	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Won Park, Paweł Hrycaj, Sławomir Jeka et al. · Annals of the Rheumatic Diseases Open access	18 May 2013	607
3	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study Kathryn M. Hastie et al. · Science Open access	23 Sep 2021	343
4	Physicochemical characterization of Remsima® Soon Kwan Jung, Kyoung Hoon Lee, Jae Won Jeon et al. · mAbs Open access	5 Aug 2014	341
5	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein Cheol-Min Kim et al. · Nature Communications Open access	12 Jan 2021	302
6	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study Dae‐Hyun Yoo, Nenad Prodanović, Janusz Jaworski et al. · Annals of the Rheumatic Diseases Open access	30 Apr 2016	281
7	Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn et al. · Gastroenterology Open access	5 Mar 2021	234
8	Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study Won Park, Dae‐Hyun Yoo, Pedro Cavaleiro Miranda et al. · Annals of the Rheumatic Diseases Open access	27 Apr 2016	229
9	Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study Byong Duk Ye, Marina Pesegova, Olga Alexeeva et al. · The Lancet Open access	28 Mar 2019	212
10	Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima Shomron Ben‐Horin, Miri Yavzori, Itai Benhar et al. · Gut	20 Apr 2015	177
11	A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study Dae‐Hyun Yoo, Artur J. Racewicz, Jan Brzezicki et al. · Arthritis Research & Therapy Open access	2 Apr 2016	171
12	A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus Ying Wu et al. · Nature Communications Open access	21 Jul 2015	155
13	Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study Won Park, Dae‐Hyun Yoo, Janusz Jaworski et al. · Arthritis Research & Therapy Open access	20 Jan 2016	140
14	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial Justin Stebbing, Yauheni Valerievich Baranau, Valeriy Baryash et al. · The Lancet Oncology Open access	4 Jun 2017	123
15	Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea Sang Hyoung Park, Young Ho Kim, Young-Ho Kim et al. · Expert Review of Gastroenterology & Hepatology Open access	22 Sep 2015	111
16	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases HoUng Kim, Rieke Alten, Luisa Avedano et al. · Drugs Open access	30 Jan 2020	102
17	Biosimilars for the management of rheumatoid arthritis: economic considerations László Gulàcsi, Valentin Brodszky, Petra Baji et al. · Expert Review of Clinical Immunology Open access	22 Sep 2015	95
18	Inhibition of Homodimerization of Toll-like Receptor 4 by 6-Shogaol Sang‐Il Ahn, Jun-Kyung Lee, Hyung‐Sun Youn · Molecules and Cells Open access	Feb 2009	92
19	Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health Jürgen Braun, Alex Kudrin · Biologicals Open access	30 Apr 2016	91
20	A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma Julie E. Bauman, Hugo Arias‐Pulido, Sang Joon Lee et al. · Oral Oncology Open access	4 Feb 2013	86
21	A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis Dae‐Hyun Yoo et al. · Annals of the Rheumatic Diseases Open access	14 Sep 2016	83
22	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis Tsutomu Takeuchi, Hisashi Yamanaka, Yoshiya Tanaka et al. · Modern Rheumatology Open access	4 Mar 2015	83
23	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial Won Seog Kim, Christian Buske, Michinori Ogura et al. · The Lancet Haematology Open access	14 Jul 2017	76
24	Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial Ji Cheol Bae, Won‐Young Lee, Kun‐Ho Yoon et al. · Diabetes Care	15 Apr 2015	76
25	Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) Stephen B. Hanauer et al. · Gastroenterology Open access	23 May 2024	69
26	The Path Towards a Tailored Clinical Biosimilar Development Martin Schiestl, Gopinath M. Ranganna, Keith D. Watson et al. · BioDrugs Open access	7 Apr 2020	68
27	Prevention of free fatty acid‐induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction Dae Won Jun, Won Kyeong Cho, Jin Hyun Jun et al. · Liver International	2 Aug 2011	66
28	Fungal Degradation of the Bioplastic PHB (Poly-3-hydroxy- butyric acid) K.-M. Lee, D. F. Gimore, Martin J. Huss · Journal of Polymers and the Environment	Jul 2005	65
29	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial Michinori Ogura et al. · The Lancet Haematology Open access	30 Oct 2018	64
30	Evaluation of a Dual-Wavelength Size Exclusion HPLC Method With Improved Sensitivity to Detect Protein Aggregates and Its Use to Better Characterize Degradation Pathways of an IgG1 Monoclonal Antibody Michael D. Bond, Mark E. Panek, Zheru Zhang et al. · Journal of Pharmaceutical Sciences	28 Dec 2009	64
31	Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product Kyoung Hoon Lee, Jihun Lee, Jin Soo Bae et al. · mAbs Open access	22 Feb 2018	62
32	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab Yoshiya Tanaka, Hisashi Yamanaka, Tsutomu Takeuchi et al. · Modern Rheumatology Open access	Sep 2016	61
33	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Laurent Peyrin‐Biroulet, Perttu E. T. Arkkila, Alessandro Armuzzi et al. · BMC Gastroenterology ReviewOpen access	8 Jun 2022	58
34	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant Dong-Kyun Ryu, Rina Song, Minsoo Kim et al. · Biochemical and Biophysical Research Communications Open access	7 Jun 2021	57
35	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial René Westhovens et al. · Lara D. Veeken Open access	17 Aug 2020	57
36	Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth Kunho Chung, Irfan Ullah, Nahyeon Kim et al. · Journal of drug targeting	19 Dec 2019	57
37	Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial Won Park et al. · mAbs Open access	16 Jul 2018	55
38	Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses Jihun Lee, Hyun Ah Kang, Jin Soo Bae et al. · mAbs Open access	26 Feb 2018	52
39	Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study Won Park, Sang Joon Lee, Jihye Yun et al. · Expert Review of Clinical Immunology Open access	22 Sep 2015	49
40	Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection Jin Yong Kim, Young Rock Jang, Jang Hee Hong et al. · Clinical Therapeutics Open access	22 Aug 2021	48
41	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial Seung Cheol Shim et al. · Lara D. Veeken Open access	6 Apr 2019	48
42	Monoclonal antibody therapies in the management of SARS-CoV-2 infection Enrique Míguez‐Rey, Dasom Choi, Seungmin Kim et al. · Expert Opinion on Investigational Drugs Open access	2 Jan 2022	46
43	An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements Christian Buske, Michinori Ogura, Hyuk-Chan Kwon et al. · Future Oncology Open access	9 May 2017	45
44	Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis Darian Williams et al. · eLife Open access	11 Jan 2022	44
45	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis Won Park, Chang‐Hee Suh, Seung Cheol Shim et al. · BioDrugs Open access	9 Jun 2017	44
46	The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Shomron Ben‐Horin, Graham Heap, Tariq Ahmad et al. · Expert Review of Gastroenterology & Hepatology Open access	22 Sep 2015	44
47	Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019 Anca Streinu-Cercel, Oana Săndulescu, Liliana Preoțescu et al. · Open Forum Infectious Diseases Open access	2 Feb 2022	43
48	The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2 Dong-Kyun Ryu et al. · Biochemical and Biophysical Research Communications Open access	13 Sep 2021	41
49	Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13) Ji Soo Kim, Sung Hwan Kim, ByoungOh Kwon et al. · Expert Review of Clinical Immunology Open access	22 Sep 2015	39
50	Fisetin induces apoptosis in Huh-7 cells via downregulation of BIRC8 and Bcl2L2 Ju Yeon Kim, Young Keul Jeon, Won Kyung Jeon et al. · Food and Chemical Toxicology	26 May 2010	39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.